» Articles » PMID: 28954101

Molecular Basis of Basal Cell Carcinoma

Overview
Specialty Dermatology
Date 2017 Sep 28
PMID 28954101
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Basal cell carcinoma is the most common cancer, presenting low mortality but high morbidity, and it has as risk factor exposure to sunlight, especially UVB spectrum. The most important constitutional risk factors for basal cell carcinoma development are clear phototypes (I and II, Fitzpatrick classification), family history of basal cell carcinoma (30-60%), freckles in childhood, eyes and light hair. The environmental risk factor better established is exposure to ultraviolet radiation. However, different solar exposure scenarios probably are independent risk factors for certain clinical and histological types, topographies and prognosis of this tumor, and focus of controversy among researchers. Studies confirm that changes in cellular genes Hedgehog signaling pathway are associated with the development of basal cell carcinoma. The cellular Hedgehog signaling pathway is activated in organogenesis, but is altered in various types of tumors.

Citing Articles

Exploring the Role of Symptom Diversity in Facial Basal Cell Carcinoma: Key Insights into Preoperative Quality of Life and Disease Progression.

Stundys D, Kucinskaite A, Gervickaite S, Grigaitiene J, Tutkuviene J, Jancoriene L Cancers (Basel). 2025; 17(1.

PMID: 39796765 PMC: 11720226. DOI: 10.3390/cancers17010138.


Targeted Drug Delivery in Periorbital Non-Melanocytic Skin Malignancies.

Tirone B, Scarabosio A, Surico P, Parodi P, DEsposito F, Avitabile A Bioengineering (Basel). 2024; 11(10).

PMID: 39451404 PMC: 11504966. DOI: 10.3390/bioengineering11101029.


Personalized treatment concepts in extraocular cancer.

Ju S, Rokohl A, Guo Y, Yao K, Fan W, Heindl L Adv Ophthalmol Pract Res. 2024; 4(2):69-77.

PMID: 38590555 PMC: 10999489. DOI: 10.1016/j.aopr.2024.02.003.


Genetic Variations Related to Angiotensin II Production and Risk for Basal Cell Carcinoma.

Gintoni I, Mastrogeorgiou M, Papakosta V, Vassiliou S, Yapijakis C Biochem Genet. 2024; .

PMID: 38546913 DOI: 10.1007/s10528-024-10746-0.


Review of recent advances in managing periocular skin malignancies.

Trotier D, Huang L, van Landingham S, Burr A, Ma V Front Oncol. 2024; 14:1275930.

PMID: 38500654 PMC: 10944901. DOI: 10.3389/fonc.2024.1275930.


References
1.
Dreier J, Dummer R, Felderer L, Nageli M, Gobbi S, Kunstfeld R . Emerging drugs and combination strategies for basal cell carcinoma. Expert Opin Emerg Drugs. 2014; 19(3):353-65. DOI: 10.1517/14728214.2014.914171. View

2.
Ruiz Lascano A, Kuznitzky R, Garay I, Ducasse C, Albertini R . [Risk factors for basal cell carcinoma. Case-control study in Cordoba]. Medicina (B Aires). 2006; 65(6):495-500. View

3.
Liang M, Lv J, Chu H, Wang J, Chen X, Zhu X . Vertical inhibition of PI3K/Akt/mTOR signaling demonstrates in vitro and in vivo anti-fibrotic activity. J Dermatol Sci. 2014; 76(2):104-11. DOI: 10.1016/j.jdermsci.2014.08.002. View

4.
Hahn H, Wicking C, Zaphiropoulous P, Gailani M, Shanley S, Chidambaram A . Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996; 85(6):841-51. DOI: 10.1016/s0092-8674(00)81268-4. View

5.
Donovan J . Review of the hair follicle origin hypothesis for basal cell carcinoma. Dermatol Surg. 2009; 35(9):1311-23. DOI: 10.1111/j.1524-4725.2009.01236.x. View